Trade AstraZeneca PLC - SEK - AZNs CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 4.5 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.021947% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.000275% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | SEK | ||||||||
Margin | 5% | ||||||||
Stock exchange | Sweden | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
AstraZeneca PLC ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 1324 |
Open* | 1328.5 |
1-Year Change* | -6.73% |
Day's Range* | 1325 - 1335.5 |
52 wk Range | 100.12-123.92 |
Average Volume (10 days) | 1.31M |
Average Volume (3 months) | 34.89M |
Market Cap | 156.89B |
P/E Ratio | 33.46 |
Shares Outstanding | 1.55B |
Revenue | 36.02B |
EPS | 3.03 |
Dividend (Yield %) | 2.326 |
Beta | 0.29 |
Next Earnings Date | Feb 8, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 8, 2023 | 1328.0 | 8.0 | 0.61% | 1320.0 | 1337.0 | 1318.0 |
Dec 7, 2023 | 1324.0 | 0.0 | 0.00% | 1324.0 | 1341.5 | 1316.0 |
Dec 6, 2023 | 1339.0 | -9.0 | -0.67% | 1348.0 | 1356.5 | 1338.0 |
Dec 5, 2023 | 1346.0 | -8.5 | -0.63% | 1354.5 | 1357.0 | 1335.0 |
Dec 4, 2023 | 1356.0 | 14.0 | 1.04% | 1342.0 | 1358.0 | 1337.0 |
Dec 1, 2023 | 1348.5 | 3.5 | 0.26% | 1345.0 | 1365.4 | 1341.5 |
Nov 30, 2023 | 1341.5 | 21.0 | 1.59% | 1320.5 | 1346.0 | 1316.0 |
Nov 29, 2023 | 1324.0 | 19.5 | 1.49% | 1304.5 | 1334.0 | 1303.0 |
Nov 28, 2023 | 1308.0 | -15.0 | -1.13% | 1323.0 | 1324.0 | 1307.0 |
Nov 27, 2023 | 1328.0 | -10.5 | -0.78% | 1338.5 | 1350.5 | 1325.5 |
Nov 24, 2023 | 1348.5 | 3.0 | 0.22% | 1345.5 | 1353.5 | 1342.5 |
Nov 23, 2023 | 1348.0 | 31.5 | 2.39% | 1316.5 | 1348.5 | 1316.5 |
Nov 22, 2023 | 1331.5 | -11.5 | -0.86% | 1343.0 | 1346.5 | 1330.0 |
Nov 21, 2023 | 1334.5 | 11.5 | 0.87% | 1323.0 | 1336.5 | 1323.0 |
Nov 20, 2023 | 1328.0 | -12.0 | -0.90% | 1340.0 | 1340.0 | 1318.5 |
Nov 17, 2023 | 1350.0 | -5.0 | -0.37% | 1355.0 | 1364.4 | 1345.0 |
Nov 16, 2023 | 1346.5 | 19.0 | 1.43% | 1327.5 | 1347.0 | 1326.0 |
Nov 15, 2023 | 1332.5 | -31.9 | -2.34% | 1364.4 | 1368.9 | 1330.5 |
Nov 14, 2023 | 1365.9 | -12.5 | -0.91% | 1378.4 | 1383.4 | 1362.9 |
Nov 13, 2023 | 1371.4 | 3.5 | 0.26% | 1367.9 | 1387.9 | 1361.0 |
AstraZeneca PLC - SEK Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 44351 | 37417 | 26617 | 24384 | 22090 |
Revenue | 44351 | 37417 | 26617 | 24384 | 22090 |
Cost of Revenue, Total | 8649 | 9542 | 5270 | 4824 | 4246 |
Gross Profit | 35702 | 27875 | 21347 | 19560 | 17844 |
Total Operating Expense | 40594 | 36361 | 21455 | 21460 | 18703 |
Selling/General/Admin. Expenses, Total | 13512 | 11519 | 9338 | 8964 | 8479 |
Research & Development | 9612 | 8519 | 6094 | 5320 | 5266 |
Depreciation / Amortization | 4094 | 3044 | 1897 | 1812 | 1945 |
Unusual Expense (Income) | 5071 | 3846 | -763 | 863 | -953 |
Other Operating Expenses, Total | -344 | -109 | -381 | -323 | -280 |
Operating Income | 3757 | 1056 | 5162 | 2924 | 3387 |
Interest Income (Expense), Net Non-Operating | -815 | -819 | -716 | -766 | -775 |
Other, Net | -441 | -502 | -530 | -610 | -619 |
Net Income Before Taxes | 2501 | -265 | 3916 | 1548 | 1993 |
Net Income After Taxes | 3293 | 115 | 3144 | 1227 | 2050 |
Minority Interest | -5 | -3 | 52 | 108 | 105 |
Net Income Before Extra. Items | 3288 | 112 | 3196 | 1335 | 2155 |
Net Income | 3288 | 112 | 3196 | 1335 | 2155 |
Income Available to Common Excl. Extra. Items | 3288 | 112 | 3196 | 1335 | 2155 |
Income Available to Common Incl. Extra. Items | 3288 | 112 | 3196 | 1335 | 2155 |
Dilution Adjustment | 0 | 0 | |||
Diluted Net Income | 3288 | 112 | 3196 | 1335 | 2155 |
Diluted Weighted Average Shares | 1560 | 1427 | 1313 | 1301 | 1267 |
Diluted EPS Excluding Extraordinary Items | 2.10769 | 0.07849 | 2.43412 | 1.02613 | 1.70087 |
Dividends per Share - Common Stock Primary Issue | 2.89361 | 2.84245 | 2.83031 | 2.89446 | 2.74532 |
Diluted Normalized EPS | 4.04679 | 2.22705 | 1.88804 | 1.48501 | 0.85399 |
Interest Expense (Income) - Net Operating | 0 | 0 | |||
Total Extraordinary Items |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 11416 | 10879 | 11207 | 10982 | 10771 |
Revenue | 11416 | 10879 | 11207 | 10982 | 10771 |
Cost of Revenue, Total | 1925 | 1782 | 2417 | 2118 | 1904 |
Gross Profit | 9491 | 9097 | 8790 | 8864 | 8867 |
Total Operating Expense | 8960 | 8330 | 10113 | 9737 | 10232 |
Selling/General/Admin. Expenses, Total | 3592 | 3196 | 3469 | 3353 | 3340 |
Research & Development | 2570 | 2299 | 2525 | 2357 | 2431 |
Depreciation / Amortization | 952 | 954 | 1034 | 979 | 983 |
Unusual Expense (Income) | -285 | 379 | 641 | 1002 | 1298 |
Other Operating Expenses, Total | 206 | -280 | 27 | -72 | 276 |
Operating Income | 2456 | 2549 | 1094 | 1245 | 539 |
Interest Income (Expense), Net Non-Operating | -368 | -287 | -316 | -323 | -292 |
Net Income Before Taxes | 2088 | 2262 | 778 | 922 | 247 |
Net Income After Taxes | 1820 | 1804 | 902 | 1642 | 360 |
Minority Interest | -2 | -1 | -1 | -2 | 0 |
Net Income Before Extra. Items | 1818 | 1803 | 901 | 1640 | 360 |
Net Income | 1818 | 1803 | 901 | 1640 | 360 |
Income Available to Common Excl. Extra. Items | 1818 | 1803 | 901 | 1640 | 360 |
Income Available to Common Incl. Extra. Items | 1818 | 1803 | 901 | 1640 | 360 |
Dilution Adjustment | |||||
Diluted Net Income | 1818 | 1803 | 901 | 1640 | 360 |
Diluted Weighted Average Shares | 1560 | 1560 | 1560 | 1559 | 1560 |
Diluted EPS Excluding Extraordinary Items | 1.16538 | 1.15577 | 0.57756 | 1.05196 | 0.23077 |
Dividends per Share - Common Stock Primary Issue | 0.91215 | 0 | 1.9694 | 0 | 0.93017 |
Diluted Normalized EPS | 1.00614 | 1.34953 | 0.90705 | 0.99743 | 0.80833 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 22593 | 26244 | 19544 | 15563 | 15591 |
Cash and Short Term Investments | 6405 | 6398 | 7992 | 6218 | 5680 |
Cash | 1411 | 1461 | 1182 | 755 | 893 |
Cash & Equivalents | 4755 | 4868 | 6650 | 4614 | 3938 |
Short Term Investments | 239 | 69 | 160 | 849 | 849 |
Total Receivables, Net | 9923 | 8795 | 5651 | 5181 | 4345 |
Accounts Receivable - Trade, Net | 7508 | 6324 | 3956 | 3813 | 2995 |
Total Inventory | 4699 | 8983 | 4024 | 3193 | 2890 |
Prepaid Expenses | 1329 | 1512 | 1735 | 865 | 1436 |
Other Current Assets, Total | 237 | 556 | 142 | 106 | 1240 |
Total Assets | 96483 | 105363 | 66729 | 61377 | 60651 |
Property/Plant/Equipment, Total - Net | 9449 | 10171 | 8917 | 8335 | 7421 |
Property/Plant/Equipment, Total - Gross | 17192 | 18495 | 17110 | 15852 | 14639 |
Accumulated Depreciation, Total | -7743 | -8324 | -8193 | -7517 | -7218 |
Goodwill, Net | 19820 | 19997 | 11845 | 11668 | 11707 |
Intangibles, Net | 39307 | 42387 | 20947 | 20833 | 21959 |
Long Term Investments | 1142 | 1237 | 1147 | 1459 | 922 |
Note Receivable - Long Term | 592 | 504 | 325 | 348 | 515 |
Other Long Term Assets, Total | 3580 | 4823 | 4004 | 3171 | 2536 |
Total Current Liabilities | 26293 | 22594 | 20307 | 18117 | 16292 |
Accounts Payable | 2550 | 2824 | 2350 | 1774 | 1720 |
Accrued Expenses | 8303 | 8079 | 4994 | 5085 | 5148 |
Notes Payable/Short Term Debt | 261 | 294 | 370 | 154 | 160 |
Current Port. of LT Debt/Capital Leases | 5281 | 1599 | 2016 | 1856 | 1594 |
Other Current Liabilities, Total | 9898 | 9798 | 10577 | 9248 | 7670 |
Total Liabilities | 59446 | 66095 | 51107 | 48250 | 48183 |
Total Long Term Debt | 23690 | 28888 | 17994 | 16217 | 17359 |
Long Term Debt | 22965 | 28134 | 17505 | 15730 | 17359 |
Capital Lease Obligations | 725 | 754 | 489 | 487 | 0 |
Deferred Income Tax | 2944 | 6206 | 2918 | 2490 | 3286 |
Minority Interest | 21 | 19 | 16 | 1469 | 1576 |
Other Liabilities, Total | 6498 | 8388 | 9872 | 9957 | 9670 |
Total Equity | 37037 | 39268 | 15622 | 13127 | 12468 |
Common Stock | 387 | 387 | 328 | 328 | 317 |
Additional Paid-In Capital | 35155 | 35126 | 7971 | 7941 | 4427 |
Retained Earnings (Accumulated Deficit) | 1495 | 3755 | 7323 | 4858 | 7724 |
Total Liabilities & Shareholders’ Equity | 96483 | 105363 | 66729 | 61377 | 60651 |
Total Common Shares Outstanding | 1549.8 | 1549.4 | 1312.67 | 1312.14 | 1267.04 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 22501 | 22839 | 22266 | 22593 | 20224 |
Cash and Short Term Investments | 5115 | 5812 | 6462 | 6405 | 4898 |
Cash & Equivalents | 4871 | 5664 | 6232 | 6166 | 4458 |
Short Term Investments | 244 | 148 | 230 | 239 | 440 |
Total Receivables, Net | 11997 | 11932 | 10797 | 11252 | 10061 |
Accounts Receivable - Trade, Net | 11300 | 11092 | 10289 | 10521 | 9336 |
Total Inventory | 5292 | 5051 | 4967 | 4699 | 5078 |
Other Current Assets, Total | 97 | 44 | 40 | 237 | 187 |
Total Assets | 96086 | 96543 | 96687 | 96483 | 94185 |
Property/Plant/Equipment, Total - Net | 9700 | 9624 | 9599 | 9449 | 9227 |
Goodwill, Net | 19939 | 19960 | 20001 | 19820 | 19707 |
Intangibles, Net | 37687 | 38326 | 39291 | 39307 | 39585 |
Long Term Investments | 1290 | 1143 | 1234 | 1142 | 1102 |
Note Receivable - Long Term | 761 | 752 | 682 | 835 | 792 |
Other Long Term Assets, Total | 4208 | 3899 | 3614 | 3337 | 3548 |
Total Current Liabilities | 28588 | 26375 | 24860 | 26293 | 24850 |
Payable/Accrued | 20542 | 19738 | 19210 | 19040 | 17694 |
Notes Payable/Short Term Debt | 331 | 271 | 568 | 261 | 584 |
Current Port. of LT Debt/Capital Leases | 5276 | 4516 | 3289 | 5281 | 5034 |
Other Current Liabilities, Total | 2439 | 1850 | 1793 | 1711 | 1538 |
Total Liabilities | 58889 | 59151 | 60898 | 59446 | 59051 |
Total Long Term Debt | 22969 | 25051 | 27646 | 23690 | 23681 |
Long Term Debt | 22225 | 24329 | 26916 | 22965 | 23013 |
Capital Lease Obligations | 744 | 722 | 730 | 725 | 668 |
Deferred Income Tax | 2752 | 2800 | 2795 | 2944 | 3479 |
Minority Interest | 24 | 24 | 22 | 21 | 20 |
Other Liabilities, Total | 4556 | 4901 | 5575 | 6498 | 7021 |
Total Equity | 37197 | 37392 | 35789 | 37037 | 35134 |
Common Stock | 387 | 387 | 387 | 387 | 387 |
Additional Paid-In Capital | 35166 | 35163 | 35159 | 35155 | 35137 |
Retained Earnings (Accumulated Deficit) | 1644 | 1842 | 243 | 1495 | -390 |
Total Liabilities & Shareholders’ Equity | 96086 | 96543 | 96687 | 96483 | 94185 |
Total Common Shares Outstanding | 1549.91 | 1549.88 | 1549.85 | 1549.8 | 1549.51 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 2501 | -265 | 3916 | 1548 | 1993 |
Cash From Operating Activities | 9808 | 5963 | 4799 | 2969 | 2618 |
Cash From Operating Activities | 5480 | 6530 | 3149 | 3762 | 3753 |
Non-Cash Items | 542 | 141 | -332 | -103 | -1276 |
Cash Taxes Paid | 1623 | 1743 | 1562 | 1118 | 537 |
Cash Interest Paid | 849 | 721 | 733 | 774 | 676 |
Changes in Working Capital | 1285 | -443 | -1934 | -2238 | -1852 |
Cash From Investing Activities | -2960 | -11058 | -285 | -657 | 963 |
Capital Expenditures | -2571 | -2200 | -2606 | -2460 | -1371 |
Other Investing Cash Flow Items, Total | -389 | -8858 | 2321 | 1803 | 2334 |
Cash From Financing Activities | -6823 | 3649 | -2203 | -1765 | -2044 |
Financing Cash Flow Items | -1047 | -178 | -101 | 4 | -67 |
Total Cash Dividends Paid | -4364 | -3856 | -3572 | -3592 | -3484 |
Issuance (Retirement) of Stock, Net | 29 | 29 | 30 | 3525 | 34 |
Issuance (Retirement) of Debt, Net | -1441 | 7654 | 1440 | -1702 | 1473 |
Foreign Exchange Effects | -80 | -62 | 12 | 5 | -38 |
Net Change in Cash | -55 | -1508 | 2323 | 552 | 1499 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 2262 | 2501 | 1723 | 800 | 553 |
Cash From Operating Activities | 3133 | 9808 | 7410 | 4480 | 3232 |
Cash From Operating Activities | 1502 | 5480 | 4000 | 2666 | 1309 |
Non-Cash Items | -391 | 542 | 172 | 15 | -12 |
Cash Taxes Paid | 225 | 1623 | 1335 | 1006 | 228 |
Cash Interest Paid | 257 | 849 | 608 | 386 | 194 |
Changes in Working Capital | -240 | 1285 | 1515 | 999 | 1382 |
Cash From Investing Activities | -1246 | -2960 | -2711 | -968 | -168 |
Capital Expenditures | -1470 | -2571 | -2017 | -906 | -363 |
Other Investing Cash Flow Items, Total | 224 | -389 | -694 | -62 | 195 |
Cash From Financing Activities | -2031 | -6823 | -6465 | -5035 | -3740 |
Financing Cash Flow Items | -840 | -1047 | -1047 | -997 | -997 |
Total Cash Dividends Paid | -3047 | -4364 | -4364 | -2971 | -2971 |
Issuance (Retirement) of Stock, Net | 4 | 29 | 11 | 8 | 5 |
Issuance (Retirement) of Debt, Net | 1852 | -1441 | -1065 | -1075 | 223 |
Foreign Exchange Effects | -11 | -80 | -86 | -35 | -9 |
Net Change in Cash | -155 | -55 | -1852 | -1558 | -685 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.5096 | 100893184 | 1200 | 2023-01-31 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 4.1998 | 65092368 | 768 | 2023-01-31 | LOW |
Investor AB | Private Equity | 3.3298 | 51608948 | 608 | 2023-01-31 | LOW |
Capital Research Global Investors | Investment Advisor | 3.1211 | 48374655 | -165706 | 2023-06-15 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.8719 | 44511608 | 671315 | 2023-06-15 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 2.2154 | 34336042 | 875 | 2023-10-01 | LOW |
Capital World Investors | Investment Advisor | 1.8709 | 28997204 | 474010 | 2023-06-15 | LOW |
BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 1.3307 | 20624979 | 125455 | 2023-10-01 | LOW |
BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 1.1707 | 18144143 | -35319 | 2023-10-01 | LOW |
GQG Partners, LLC | Investment Advisor | 1.0711 | 16600615 | 66511 | 2023-06-15 | MED |
Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.9319 | 14443159 | -63166 | 2023-10-01 | LOW |
State Street Global Advisors (UK) Ltd. | Investment Advisor/Hedge Fund | 0.7607 | 11789511 | 0 | 2023-10-01 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 0.6104 | 9460420 | 45825 | 2023-10-01 | LOW |
Nuveen LLC | Pension Fund | 0.5685 | 8811257 | 378713 | 2023-06-15 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5618 | 8707369 | 257289 | 2023-06-15 | LOW |
Aviva Investors Global Services Limited | Investment Advisor/Hedge Fund | 0.5266 | 8162319 | -429899 | 2023-10-01 | LOW |
Handelsbanken Kapitalförvaltning AB | Investment Advisor/Hedge Fund | 0.5212 | 8078066 | 1670 | 2023-09-30 | LOW |
M&G Investment Management Ltd. | Investment Advisor | 0.4752 | 7364510 | 948 | 2023-10-01 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.4611 | 7146065 | 10590 | 2023-10-01 | LOW |
Union Investment Privatfonds GmbH | Investment Advisor | 0.4173 | 6467102 | 30000 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
AstraZeneca - SEK Company profile
AstraZeneca is a multinational biopharmaceutical company that resulted from the merger between the Swedish Astra AB and the English Zeneca Group in 1999. The company is engaged in developing and manufacturing products to treat oncology, cardiovascular & metabolic disease (CVMD) and pursues therapies in autoimmunity, infection and neuroscience. Its R&D headquarters are located in Warsaw, Poland, while its corporate base is in London, England. AstraZeneca is listed on the stock exchanges in London, New York and Stockholm under the ticker AZN. The AZN stock belongs to the FTSE 100 Index. Follow the latest developments of the AstraZeneca share price at Capital.com.Industry: | Pharmaceuticals (NEC) |
1 Francis Crick Avenue
CAMBRIDGE
CAMBRIDGESHIRE CB2 0AA
GB
Income Statement
- Annual
- Quarterly
News

December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com